Author: Banji, David; Alqahtani, Saad S.; Banji, Otilia J.F.; Machanchery, Shamna; Shoaib, Ambreen
Title: Calming the inflammatory storm in severe COVID-19 infections: Role of biologics- A narrative review Cord-id: xng743u4 Document date: 2021_2_2
ID: xng743u4
Snippet: The risk of Coronavirus infection continues, and the fear of resurgence indicates the lack of a successful therapeutic strategy. In severe COVID-19 infection, many immune cells and their products are involved, making management difficult. The abundant release of cytokines and chemokines in severe COVID-19 patients leads to profound hyper inflammation and the mobilization of immune cells, triggering the cytokine storm. The complications associated with the cytokine storm include severe respirator
Document: The risk of Coronavirus infection continues, and the fear of resurgence indicates the lack of a successful therapeutic strategy. In severe COVID-19 infection, many immune cells and their products are involved, making management difficult. The abundant release of cytokines and chemokines in severe COVID-19 patients leads to profound hyper inflammation and the mobilization of immune cells, triggering the cytokine storm. The complications associated with the cytokine storm include severe respiratory distress, intravascular coagulation, multi-organ failure, and death. The enormous formation of interleukin (IL)-6 and hemopoietic factors such as granulocyte–macrophage colony-stimulating factor (GM-CSF) are implicated in the severity of the infection. Moreover, these inflammatory cytokines and factors signal through the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway causing the activation of cytokine-related genes. The neutralization of these proteins could be of therapeutic help in COVID-19 patients and could mitigate the risk of mortality. IL-6 antagonist, IL-6 receptor antagonists, GM-CSF receptor inhibitors, and JAK-STAT inhibitors are being investigated to prevent intense lung injury in COVID-19 patients and increase the chances of survival. The review focuses the role of IL-6, GM-CSF, and JAK-STAT inhibitors in regulating the immune response in severely affected COVID-19 patients.
Search related documents:
Co phrase search for related documents- acute ards respiratory distress syndrome and adaptive immune system: 1, 2, 3, 4
- acute ards respiratory distress syndrome and adaptive immune system innate: 1, 2, 3
- acute ards respiratory distress syndrome and adaptor protein: 1
- acute ards respiratory distress syndrome and liver function: 1, 2, 3, 4, 5, 6, 7, 8
- acute ards respiratory distress syndrome and low protein: 1, 2, 3, 4
- acute ards respiratory distress syndrome and lung compliance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49
- acute ards respiratory distress syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute ards respiratory distress syndrome and lung hyper: 1, 2
- acute ards respiratory distress syndrome and lung hyper inflammation: 1
- acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
- acute ards respiratory distress syndrome and lung injury evident: 1, 2, 3
- acute ards respiratory distress syndrome and lung involvement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
- acute ards respiratory distress syndrome and lung oxygenation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31
- acute ards respiratory distress syndrome and lung repair: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- acute ards respiratory distress syndrome and m1 phenotype: 1, 2
- acute ards respiratory distress syndrome and macrophage inflammatory protein: 1, 2, 3, 4, 5
- acute ards respiratory distress syndrome and macrophage monocyte differentiation: 1, 2
- acute ards respiratory distress syndrome and macrophage surface: 1
- acute host versus graft disease and adaptive immune response: 1
Co phrase search for related documents, hyperlinks ordered by date